CO5271710A1 - Combinanciones de un inhibidor de cinasa de tirosina receptora con un compuesto organico capaz de enlazarse con glicorpoteina acido-a - Google Patents

Combinanciones de un inhibidor de cinasa de tirosina receptora con un compuesto organico capaz de enlazarse con glicorpoteina acido-a

Info

Publication number
CO5271710A1
CO5271710A1 CO00097404A CO00097404A CO5271710A1 CO 5271710 A1 CO5271710 A1 CO 5271710A1 CO 00097404 A CO00097404 A CO 00097404A CO 00097404 A CO00097404 A CO 00097404A CO 5271710 A1 CO5271710 A1 CO 5271710A1
Authority
CO
Colombia
Prior art keywords
receptor
kinase inhibitor
acid
abl tyrosine
glycorpothine
Prior art date
Application number
CO00097404A
Other languages
English (en)
Inventor
Carlo Gambacorti-P
Philipp Lecoutre
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO5271710A1 publication Critical patent/CO5271710A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La presente invención se relaciona con combinaciones de un inhibidor de cinasa de tirosina de abl, receptora de PDGF, y/o receptora de Kit, con un compuesto orgánico capaz de enlazarse con licoproteína ácida-a1 (AGP), así como a preparaciones farmacéuticas y/o terapias, en relación con estados de enfermedad que respondan a la inhibición de cinasa de tirosina de abl, receptora PDGF, y/o receptora de Kit. En particular, la invención se refiere a productos o combinaciones que comprenden un inhibidor de cinasa de tirosina de abl, receptora de PDGF y/o receptora de Kit con un compuesto orgánico capaz de enlazarse con AGP, en una combinación fija, o para su administración cronológicamente escalonada o simultánea, y al uso combinado de ambas clases de compuestos, ya sea en una combinación fija, o para su administración cronológicamente escalonada o simultánea, para el tratamiento de enfermedades proliferativas, especialmente enfermedades tumorales especialmente aquéllas que se puedan tratar mediante la inhibición de la actividad de cinasa tirosina de abl, receptora de PDGF, y/o receptora de Kit.
CO00097404A 1999-12-27 2000-12-22 Combinanciones de un inhibidor de cinasa de tirosina receptora con un compuesto organico capaz de enlazarse con glicorpoteina acido-a CO5271710A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1999MI002711A ITMI992711A1 (it) 1999-12-27 1999-12-27 Composti organici

Publications (1)

Publication Number Publication Date
CO5271710A1 true CO5271710A1 (es) 2003-04-30

Family

ID=11384195

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00097404A CO5271710A1 (es) 1999-12-27 2000-12-22 Combinanciones de un inhibidor de cinasa de tirosina receptora con un compuesto organico capaz de enlazarse con glicorpoteina acido-a

Country Status (18)

Country Link
US (2) US20030125343A1 (es)
EP (1) EP1250140B1 (es)
JP (1) JP2003523325A (es)
CN (1) CN1304005C (es)
AR (1) AR030179A1 (es)
AT (1) ATE432069T1 (es)
AU (1) AU2171901A (es)
BR (1) BR0016817A (es)
CA (1) CA2394944A1 (es)
CO (1) CO5271710A1 (es)
DE (1) DE60042283D1 (es)
ES (1) ES2326307T3 (es)
HK (1) HK1050993A1 (es)
IT (1) ITMI992711A1 (es)
PE (1) PE20010991A1 (es)
PT (1) PT1250140E (es)
TW (1) TWI246917B (es)
WO (1) WO2001047507A2 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60130017T2 (de) * 2000-11-22 2008-05-15 Novartis Ag Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität
US6878697B2 (en) 2001-06-21 2005-04-12 Ariad Pharmaceuticals, Inc. Phenylamino-pyrimidines and uses thereof
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
US7323469B2 (en) 2001-08-07 2008-01-29 Novartis Ag 7H-pyrrolo[2,3-d]pyrimidine derivatives
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
MXPA04003878A (es) * 2001-10-25 2004-07-08 Novartis Ag Combinaciones que comprenden un inhibidor selectivo de cicloxigenasa-2.
GB0201508D0 (en) 2002-01-23 2002-03-13 Novartis Ag Organic compounds
US20060128720A1 (en) * 2002-03-21 2006-06-15 Kufe Donald W Inhibition of cell death responses induced by oxidative stress
AU2007201830C1 (en) * 2002-04-23 2017-09-07 Novartis Pharma Ag High drug load tablet
GB0209265D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US20060052387A1 (en) * 2002-06-26 2006-03-09 Marsh Clay B Organic compounds
BR0312821A (pt) * 2002-07-24 2005-04-19 Akira Ohtsuru 4-(4-metil-piperazin-1-il-metil)-n-[(4-metil-3-(4-piridin-3-i l)-pirimidin-2-il-amino)-fenil]-benzamida para tratar câncer anaplásico da tireóide
EP1542989B1 (en) * 2002-07-31 2007-04-18 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
GB0222514D0 (en) 2002-09-27 2002-11-06 Novartis Ag Organic compounds
ATE380810T1 (de) * 2002-10-09 2007-12-15 Critical Outcome Technologies Protein-tyrosine-kinase-inhibitoren
AU2003268185A1 (en) * 2003-08-25 2005-04-11 Dana-Farber Cancer Institute Inc. Method of treating mixed lineage leukemia gene-rearranged acute lymphoblastic leukemias
CN100467064C (zh) * 2003-09-19 2009-03-11 诺瓦提斯公司 伊马替尼和米哚妥林在制备治疗胃肠道基质肿瘤药物中的应用
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
PL1720853T3 (pl) † 2004-02-11 2016-06-30 Natco Pharma Ltd Nowa odmiana polimorficzna metanosulfonianu imatynibu i sposób jej otrzymywania
US7358250B2 (en) 2004-06-29 2008-04-15 Amgen Inc. Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity
JP2008508358A (ja) * 2004-08-02 2008-03-21 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド アリール−アミノ置換ピロロピリミジンマルチキナーゼ阻害化合物
ATE519759T1 (de) 2004-12-30 2011-08-15 Exelixis Inc Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren
US20070059359A1 (en) * 2005-06-07 2007-03-15 Thomas Backensfeld Immediate-release and high-drug-load pharmaceutical formulations of non-micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
US20060275365A1 (en) * 2005-06-07 2006-12-07 Thomas Backensfeld Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl) [4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
US20080214445A1 (en) * 2005-06-23 2008-09-04 Sebastien Bihorel Method of Treating a Solid Tumor Disease Comprising Administering a Combination Comprising Imatinib and an Inhibitor of an Efflux Pump Active at the Blood Brain Barrier or Demethyl Imatinib
RU2441869C2 (ru) * 2005-12-21 2012-02-10 Эбботт Лэборетриз Противовирусные соединения
EP1971611B1 (en) 2005-12-21 2012-10-10 Abbott Laboratories Anti-viral compounds
ATE475660T1 (de) 2005-12-21 2010-08-15 Abbott Lab Antivirale verbindungen
ES2458291T3 (es) * 2006-04-20 2014-04-30 Janssen Pharmaceutica Nv Derivados de amidas aromáticas como inhibidores de la cinasa C-KIT
AU2007269540B2 (en) * 2006-07-05 2013-06-27 Exelixis, Inc. Methods of using IGF1R and Abl kinase modulators
US8236950B2 (en) 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
EP2121681B1 (en) 2007-01-11 2015-04-15 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
US20080248548A1 (en) * 2007-04-09 2008-10-09 Flynn Daniel L Modulation of protein functionalities
WO2009042803A1 (en) * 2007-09-25 2009-04-02 Teva Pharmaceutical Industries Ltd. Imatinib compositions
WO2009079797A1 (en) * 2007-12-26 2009-07-02 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
EA201070841A1 (ru) 2008-01-11 2011-02-28 Натко Фарма Лимитед НОВЫЕ ПИРАЗОЛО[3,4-d]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПРОТИВОРАКОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
KR101956261B1 (ko) 2008-05-21 2019-03-08 어리어드 파마슈티칼스, 인코포레이티드 키나아제 억제제로서 포스포러스 유도체
EP2318406B1 (en) 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
CA2744563A1 (en) 2008-12-12 2010-06-17 Ariad Pharmaceuticals, Inc. Azaindole derivatives as kinase inhibitors
ITRM20090578A1 (it) * 2009-11-10 2011-05-11 Noi Per Voi Onlus Nuove composizioni per il trattamento di leucemie chemioresistenti e/o di leucemie potenzialmente chemioresistenti.
EP2552915B1 (en) 2010-04-01 2017-07-19 Critical Outcome Technologies Inc. Compounds for the treatment of hiv
AR083797A1 (es) 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
TR201010618A2 (tr) * 2010-12-20 2012-07-23 Bi̇lgi̇ç Mahmut İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi
PL394169A1 (pl) 2011-03-09 2012-09-10 Adamed Spółka Z Ograniczoną Odpowiedzialnością Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania
JP5999177B2 (ja) 2011-05-04 2016-09-28 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
EP2817030A1 (en) 2012-02-21 2014-12-31 Ranbaxy Laboratories Limited Stable dosage forms of imatinib mesylate
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
WO2017078647A1 (en) 2015-11-05 2017-05-11 Koçak Farma Ilaç Ve Kimya Sanayi Anonim Şirketi Pharmaceutical compositions of imatinib
EP3257499A1 (en) 2016-06-17 2017-12-20 Vipharm S.A. Process for preparation of imatinib methanesulfonate capsules

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587459A (en) * 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US5750493A (en) * 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
US20030069174A1 (en) * 1997-03-10 2003-04-10 Ludwig Pichler Use of human alpha1-acid glycoprotein for producing a pharmaceutical preparation
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
WO2001004125A1 (fr) * 1999-07-13 2001-01-18 Kyowa Hakko Kogyo Co., Ltd. Derives de staurosporine
DZ3248A1 (fr) * 1999-12-10 2001-06-14 Pfizer Prod Inc Composés à base de pyrrolo[2,3-d]pyrimidine

Also Published As

Publication number Publication date
EP1250140A2 (en) 2002-10-23
JP2003523325A (ja) 2003-08-05
ITMI992711A0 (it) 1999-12-27
WO2001047507A3 (en) 2002-04-04
CN1414858A (zh) 2003-04-30
US20030125343A1 (en) 2003-07-03
CN1304005C (zh) 2007-03-14
ATE432069T1 (de) 2009-06-15
EP1250140B1 (en) 2009-05-27
ES2326307T3 (es) 2009-10-07
AR030179A1 (es) 2003-08-13
CA2394944A1 (en) 2001-07-05
BR0016817A (pt) 2002-10-01
AU2171901A (en) 2001-07-09
US20090221519A1 (en) 2009-09-03
TWI246917B (en) 2006-01-11
DE60042283D1 (de) 2009-07-09
PE20010991A1 (es) 2001-10-23
ITMI992711A1 (it) 2001-06-27
HK1050993A1 (zh) 2003-07-18
PT1250140E (pt) 2009-08-24
WO2001047507A2 (en) 2001-07-05

Similar Documents

Publication Publication Date Title
CO5271710A1 (es) Combinanciones de un inhibidor de cinasa de tirosina receptora con un compuesto organico capaz de enlazarse con glicorpoteina acido-a
BRPI0606996A2 (pt) combinação de compostos orgánicos, uso da mesma e composição farmacêutica
BRPI0612845A8 (pt) composto, formulação farmacêutica, métodos para tratar câncer e para sintetizar um composto de fórmula alq-dispasador
CR8181A (es) Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer
ECSP055840A (es) Derivados de 4 -tetrazolil-4fenilpiperidina para el tratamiento del dolor
ECSP055525A (es) Inhibidores de cinasas de tirosina
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
EA200100764A1 (ru) Трициклические ингибиторы поли(adp-рибозо) полимераз
BRPI0513565A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, métodos para inibir uma atividade de proteìna cinase, e para tratar um paciente tendo uma condição que é mediada por atividade de proteìna cinase, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
BRPI0416981A (pt) compostos para tratamento de doenças proliferativas de célula
AR048502A1 (es) Sinergia terapeutica de compuestos anti-cancer
BR0309278A (pt) Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
AR044039A1 (es) Combinaciones antineoplasicas
BRPI0507482A (pt) combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap
WO2003063787A3 (en) Non-steroidal analogs of 2-methoxyestradiol
AR026197A1 (es) Uso de dipiridamol o mopidamol para el tratamiento y prevencion de trastornos de la microcirculacion dependientes de fibrina
MXPA03004209A (es) Composicion farmaceutica o cosmetica y uso de un inhbidor de proteina cinasa c con un inhibidor de metaloproteasas de la matriz para inhibir la migracion de celulas de langerhans.
ES2124983T3 (es) Utilizacion de un antagonista de substancia p para el tratamiento de las manchas rojas cutaneas de origen neurogeno.
AR049135A1 (es) Composicion,metodo, kit y tratamiento con oxaliplatino y un inhibidor del egfr,como erlotinib
AR030379A1 (es) Combinaciones
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
BRPI0408500A (pt) tratamento do diabetes do tipo 1 com inibidores de pde5
MXPA02012911A (es) Compuestos de rutenio (ii) para el uso en terapia del cancer.

Legal Events

Date Code Title Description
FC Application refused